Swiss Femtech Impli partners with Bayer for hormone monitoring

With hormones playing a critical role in many of our body’s systems and functions, real-time monitoring can help unlock key insights necessary to make smarter, more precise decisions about a person’s healthcare.

Terms of the partnership with Swiss Femtech Impli were not disclosed, but it is intended to advance early-stage research while exploring a variety of potential use cases for hormone monitoring and providing Impli with access to Bayer’s global innovation ecosystem. The partnership is the result of Impli winning a Bayer-sponsored innovation challenge at the HLTH Europe conference earlier this year.

“New technologies are helping us answer one of the largest consumer unmet needs: better understanding what is happening in their own body and what it means for managing their health journey,” said Aquil Harjivan, Head of front-end innovation for the Consumer Health division of Bayer. “We are excited to join cutting-edge innovators like Impli to explore the exciting frontiers of making health care more precise for every individual.”

“Reimagining women's hormonal health is more than a challenge; it's an opportunity to innovate and transform lives. The opportunity to break barriers together with a pioneering leader in the field such as Bayer is not just exciting—it's a chance to create meaningful change and deliver better outcomes for everyone.” said Anna Luisa Schaffgotsch CEO, Impli.

Bayer sees potential for advancements across its self-care categories with deeper understanding of a person’s hormones and their potential impact on conditions like stress, sleep, weight management, cardiovascular health, women’s health, or bone health.

(Presse release)